Literature DB >> 17846263

The relationship of Parkinson disease with aging.

Gilberto Levy1.   

Abstract

Twentieth-century hypotheses attributing a substantive role to aging in Parkinson disease (PD) pathogenesis have been countered by evidence from clinical, pathological, and biochemical investigations. However, age influences the clinical progression of PD. Several studies have demonstrated that advancing age is associated with a faster rate of motor progression, decreased levodopa responsiveness, more severe gait and postural impairment, and more severe cognitive impairment and the development of dementia in patients with PD. A model for the relationship between PD and aging is proposed that incorporates the following 3 elements: (1) There occurs a superposition of a topographic gradient of neuronal loss in brainstem and basal forebrain structures related to the disease process and an aging-related temporal gradient. (2) While PD is a chronic progressive disorder, the most important determinant of clinical progression is advancing age rather than disease duration. (3) The effects of the disease process and aging on nondopaminergic structures involve a biologic interaction. The model implies that understanding the degenerative process in nondopaminergic structures in PD as it relates to molecular mechanisms accompanying the aging of the nervous system may create opportunities for interventions affecting the clinical progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846263     DOI: 10.1001/archneur.64.9.1242

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  40 in total

1.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

2.  Dopamine content in the striatum and expression changes of Bad and Bcl-2 in elderly rats with abnormal behavior.

Authors:  Zheng-Quan Yu; Mei-Ying Liu; Qing-Xian Ren; Ye Xiong; Jian-Hui Xu; Cheng-Hua Xiao; Dian-Shuai Gao
Journal:  Neurochem Res       Date:  2011-08-05       Impact factor: 3.996

3.  Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Natalia Zarzhevsky; Robert A Koeppe; Christopher W Bogan; Michael R Kilbourn; Kirk A Frey; Roger L Albin
Journal:  Brain       Date:  2011-06-08       Impact factor: 13.501

Review 4.  Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells.

Authors:  Jenne Tran; Helena Anastacio; Cedric Bardy
Journal:  NPJ Parkinsons Dis       Date:  2020-04-24

5.  Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future.

Authors:  Anthony E Lang
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

Review 6.  Molecular Imaging of the Cholinergic System in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Martijn L T M Müller
Journal:  Int Rev Neurobiol       Date:  2018-09-20       Impact factor: 3.230

Review 7.  Oral health in geroscience: animal models and the aging oral cavity.

Authors:  Jonathan Y An; Richard Darveau; Matt Kaeberlein
Journal:  Geroscience       Date:  2017-12-27       Impact factor: 7.713

8.  Jmjd3 is essential for the epigenetic modulation of microglia phenotypes in the immune pathogenesis of Parkinson's disease.

Authors:  Y Tang; T Li; J Li; J Yang; H Liu; X J Zhang; W Le
Journal:  Cell Death Differ       Date:  2013-11-08       Impact factor: 15.828

Review 9.  Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging.

Authors:  Jing Yang; Roxana G Burciu; David E Vaillancourt
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-02       Impact factor: 5.081

10.  Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI.

Authors:  Thomas Jubault; Simona M Brambati; Clotilde Degroot; Benoît Kullmann; Antonio P Strafella; Anne-Louise Lafontaine; Sylvain Chouinard; Oury Monchi
Journal:  PLoS One       Date:  2009-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.